Schroder Adveq appeared to be the VC, which was created in 1997. The company was established in Europe in Switzerland. The leading representative office of defined VC is situated in the Zu00fcrich.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Pharmaceutical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - Switzerland. Among the various public portfolio startups of the fund, we may underline Decibel Therapeutics, Nohla Therapeutics, Memo Therapeutics
Besides them, we counted 13 critical employees of this fund in our database.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Schroder Adveq, startups are often financed by Third Rock Ventures, Venture Kick, Lightspeed China Partners. The meaningful sponsors for the fund in investment in the same round are VI Partners AG, Third Rock Ventures, Redalpine Venture Partners. In the next rounds fund is usually obtained by Vivo Capital, VI Partners AG, Third Rock Ventures.
The fund is generally included in 2-6 deals every year. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2018. The increased amount of exits for fund were in 2019. Opposing the other organizations, this Schroder Adveq works on 18 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ImmunOs Therapeutics | $77M | 07 Jun 2022 | Zurich, Switzerland | ||
HAYA Therapeutics | $5M | 09 Feb 2022 | Lausanne, Vaud, Switzerland | ||
Alentis Therapeutics | $65M | 15 Jun 2021 | Basel, Basel-City, Switzerland | ||
Tessian | $65M | 25 May 2021 | London, England, United Kingdom | ||
HAYA Therapeutics | $19M | 20 May 2021 | Lausanne, Vaud, Switzerland | ||
HAYA Therapeutics SA | $18M | 05 May 2021 | - | ||
Bizongo | $51M | 26 Apr 2021 | Mumbai, Maharashtra, India | ||
Synendos Therapeutics | $21M | 12 Nov 2020 | Basel-Country, Switzerland | ||
Memo Therapeutics | $15M | 06 Nov 2020 | Zurich, Zurich, Switzerland |
– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ImmunOs Therapeutics | $77M | 07 Jun 2022 | Zurich, Switzerland | ||
HAYA Therapeutics | $5M | 09 Feb 2022 | Lausanne, Vaud, Switzerland | ||
Alentis Therapeutics | $65M | 15 Jun 2021 | Basel, Basel-City, Switzerland | ||
Tessian | $65M | 25 May 2021 | London, England, United Kingdom | ||
HAYA Therapeutics | $19M | 20 May 2021 | Lausanne, Vaud, Switzerland | ||
HAYA Therapeutics SA | $18M | 05 May 2021 | - | ||
Bizongo | $51M | 26 Apr 2021 | Mumbai, Maharashtra, India | ||
Synendos Therapeutics | $21M | 12 Nov 2020 | Basel-Country, Switzerland | ||
Memo Therapeutics | $15M | 06 Nov 2020 | Zurich, Zurich, Switzerland |
